

DAFTAR PUSTAKA

- Budiana, I., Angelina, M., Pemayun, T. 2019. *Ovarian Cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery*. Bali: Pubmed.P: 47-54
- Akter, S., Rahman, M. A., Hasan, Akhter, H., Noor, P., Islam, R., et al. 2022. *Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements*. *Cells*.P: 1–21.
- Arora, T., Mullangi, S., & Lekkala, M. R. 2022. *Ovarian Cancer*. p 321-324
- Batool, A., Rathore, Z., Jahangir, F., Javeed, S., Nasir, S., & Chughtai, A. S. 2022. *Histopathological Spectrum of Ovarian Neoplasms: A Single-Center Study*.
- Chien, J., & Poole, E. M. 2017. *Ovarian cancer prevention, screening and early detection: Report from the 11th Biennial Ovarian Cancer Research Symposium*. *Int J Gynecol Cancer*, 27(9).P: s20–s22.
- Dilley, J., Burnell, M., Gentry-Maharaj, A., Ryan, A., Neophytou, C., Apostolidou, S., et al(2020). *Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)*. *Gynecologic Oncology*, 158(2), P: 316–322.
- Dochez, V., Randet, M., Renaudeau, C., Dimet, J., Thuaut, A. Le, Winer, N., Thubert, T.2019. *Efficacy of he4, ca125, Risk of Malignancy Index and risk of ovarian malignancy index to detect ovarian cancer in women with presumed benign ovarian tumours: A prospective, multicentre trial*. *Journal of Clinical Medicine*, 8(11), P: 1–11.
- Dora, S. K., Dandapat, A. B., Pande, B., Hota, J. P. 2017. *A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass*. *Journal of Ovarian Research*, 10(1), p: 1–9.
- Elias, K. M., Guo, J., & Bast, R. C. 2018. *Early Detection of Ovarian Cancer*. *Hematology Oncology Clin North Am*, 32(6), P: 903–914.
- Gaona, P., Medina, LA., Perez, KM. 2020. *Epidemiology of Ovarian Cancer*. *Chinese Clinical Oncology*. 9 (4): 47
- Gibson, E., Mahdy, H. 2022. *Anatomy, Abdomen, and Pelvis*, Ovary. USA.
- Global Cancer Observatory. 2020. Diakses pada: <https://gco.iarc.fr/>
- Huwidi, A., Abobrége, A., Assidi, M., Buhmeida, A., & Ermiah, E. 2022. *Diagnostic value of Risk of Malignancy Index in the clinical evaluation of ovarian mass*. *Molecular and Clinical Oncology*, 17(1), P; 1–6.
- Javdekar, R., & Maitra, N. 2015. *Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass*. *Journal of Obstetrics and Gynecology of India*, 65(2), P: 117–121
- Khoiwal, K., Bahadur, A., Kumari, R., Bhattacharya, N., Rao, S., & Chaturvedi, J. 2019. *Assessment of diagnostic value of Serum Ca-125 and Risk of Malignancy Index scoring in the evaluation of adnexal masses*. *Journal of Mid-Life Health*, 10(4), P: 192–196.
- Kurnit, K. C., Fleming, G. F., & Lengyel, E. 2021. *Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment*. *Obstetrics and Gynecology*, 137(1), P: 108–121.
- Lew, R. 2019. *Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure*. *Best Practice and Research: Clinical*

- Obstetrics and Gynaecology*, 55, P: 2–13.
- Matz, M., Coleman, M. P., Sant, M., Chirlaque, M. D., Visser, O., Gore, M., & Allemania, C. 2017. *The Histology of Ovarian Cancer: Worldwide Distribution and Implications for International Survival Comparisons (CONCORD-2)*. *Gynecologic Oncology*, 144(2), p: 405–413.
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. 2019. Ovarian cancer in the world: epidemiology and risk factors. *International Journal of Women's Health*, Volume 11, p: 287–299.
- M.Gupta, V., Chaudhary, D., & Patne, S. C. U. 2019. *Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh*. *Journal of Laboratory Physicians*, 11(01), P:075–081.
- Orsulic, S., John, J., Walts, A. E., & Gertych, A. 2022. *Computational pathology in ovarian cancer*. *Frontiers in Oncology*, 12(July), P: 1–10.
- Phung, M., Alimujang, A., Berchuck, A., Culver, H., SchilDKraut, M., Banders, E., et al. 2022. *Reproductive Faktors do not Influence survival with Ovarian Cancer*. P:909–913
- Priyanka, M., Panda, J., Samantroy, S., Panda, S., Jena, P. 2023. *Comparison of four Risk of Malignancy Indices for Preoperative Evaluatio Massses*. India: Cureus
- Stewart, C., Ralyea, C., Lockwood, S. 2019. *Ovarian Cancer: An Integrated Review*. North Caroline: Elsevier. P:1-6.
- Tantipalkorn, C., Tinnangwattana, D., Lerthiranwong, T., Luewan, S., Tongsong, T. 2023. *Comparison of effectiveness in differentiating Benign from Malignant ovarian masses between conventional and modified Risk fo Malignancy Index*
- Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. 2018. Ovarian cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*, 68(4), p: 284–296.
- Yu, K. H., Hu, V., Wang, F., Matulonis, U. A., Mutter, G. L., Golden, J. A., & Kohane, I. S. 2020. *Deciphering serous ovarian carcinoma and platinum response by convolutional neural networks*. *BMC Medicine*, 18(1), P: 1–14.
- Zhang, S., Yu, S., Hou, W., Li, X., Ning, C., Wu, Y., Zhang, F., Jiao, Y. F., Lee, L.T.O., & Sun, L. 2019. *Diagnostic extended usefulness of RMI: comparison of four Risk of Malignancy Index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors*. *Journal of Ovarian Research*
- Vallespin, C., Peruca, L., Avino, A., Bove, N., Haris, M., Borrás, M., et al. 2022. *Women'a experience along ovarian cancer diagnostic pathway in catalonia*
- WHO Classification of Tumors. 2020. *Female Genital Tumors*. 5th Edition. Swiss: International Agency for Research on Cancer. P: 31-5.